Review and management of drug interactions with boceprevir and telaprevir


  • Potential conflict of interest: Dr. Everson consults for, advises, and received grants from Vertex and Merck. Dr. Kiser received grants from Vertex and Merck.

  • This work was supported by National Institutes of Health K23 DK82321 (to J.J.K.)


Boceprevir (BOC) and telaprevir (TPV), when added to pegylated interferon and ribavirin for the treatment of chronic hepatitis C virus (HCV) infection, increase the rates of sustained virologic response in treatment-naïve persons to approximately 70%. Though these agents represent an important advance in the treatment of chronic HCV, they present new treatment challenges to the hepatology community. BOC and TPV are both substrates and inhibitors of the hepatic enzyme, cytochrome P450 3A, and the drug transporter, P-glycoprotein, which predisposes these agents to many drug interactions. Identification and appropriate management of potential drug interactions with TPV and BOC is critical for optimizing therapeutic outcomes during hepatitis C treatment. This review highlights the pharmacologic characteristics and drug-interaction potential of BOC and TPV and provides guidance on the management of drug interactions with these agents. (HEPATOLOGY 2012;)